Clinical and Angiographic Outcomes With Sirolimus-Eluting Stents in Total Coronary Occlusions

esults Patient characteristics included: diabetes, 24.5%; prior infarction, 33.5%; and stent length, 45.9 m median (quartile 1, 30.2 mm; quartile 2, 62.1 mm). A total of 199 patients (99.5%) were treated with ES, and procedural success was 98.0%. The 6-month binary restenosis rates were 9.5% in-stent, 12.4% n-segment, and 22.6% in-“working length” representing the entire treatment segment. Rates of 1-year arget lesion revascularization, myocardial infarction, and target vessel failure were 9.8%, 1.0%, and 0.9%, respectively. Stent thrombosis occurred in 2 patients (1.0%). Using logistic regression modeling ith propensity score adjustment, the absolute reduction in binary restenosis with SES compared with a istorical bare-metal stent control was 37.7% (95% confidence interval [CI]: 27.2% to 48.3%, p 0.001; dds ratio: 0.17, 95% CI: 0.09 to 0.30, p 0.0001). Among 32 patients (16%) identified with stent fracure, target lesion revascularization was more common than patients without fracture (25.0% vs. 6.7%, 0.005).